Display options
Cite
Williams SP, Karnezis T, Achen MG, et al. Targeting lymphatic vessel functions through tyrosine kinases. J Angiogenes Res. 2010;2:13doi: 10.1186/2040-2384-2-13.
Williams, S. P., Karnezis, T., Achen, M. G., & Stacker, S. A. (2010). Targeting lymphatic vessel functions through tyrosine kinases. Journal of angiogenesis research, 213. https://doi.org/10.1186/2040-2384-2-13
Williams, Steven P, et al. "Targeting lymphatic vessel functions through tyrosine kinases." Journal of angiogenesis research vol. 2 (2010): 13. doi: https://doi.org/10.1186/2040-2384-2-13
Williams SP, Karnezis T, Achen MG, Stacker SA. Targeting lymphatic vessel functions through tyrosine kinases. J Angiogenes Res. 2010 Aug 11;2:13. doi: 10.1186/2040-2384-2-13. PMID: 20698997; PMCID: PMC2925338.
Copy Download .nbib Format: NLM
Share it on

J Angiogenes Res. 2010 Aug 11;2:13. doi: 10.1186/2040-2384-2-13.

Targeting lymphatic vessel functions through tyrosine kinases.

Journal of angiogenesis research

Steven P Williams, Tara Karnezis, Marc G Achen, Steven A Stacker

Affiliations

  1. Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia. [email protected].

PMID: 20698997 PMCID: PMC2925338 DOI: 10.1186/2040-2384-2-13

Abstract

The lymphatic vascular system is actively involved in tissue fluid homeostasis, immune surveillance and fatty acid transport. Pathological conditions can arise from injury to the lymphatics, or they can be recruited in the context of cancer to facilitate metastasis. Protein tyrosine kinases are central players in signal transduction networks and regulation of cell behavior. In the lymphatic endothelium, tyrosine kinases are involved in processes such as the maintenance of existing lymphatic vessels, growth and maturation of new vessels and modulation of their identity and function. As such, they are attractive targets for both existing inhibitors and the development of new inhibitors which affect lymphangiogenesis in pathological states such as cancer. RNAi screening provides an opportunity to identify the functional role of tyrosine kinases in the lymphatics. This review will discuss the role of tyrosine kinases in lymphatic biology and the potential use of inhibitors for anti-lymphangiogenic therapy.

References

  1. Nature. 1995 Jul 6;376(6535):70-4 - PubMed
  2. N Engl J Med. 1971 Nov 18;285(21):1182-6 - PubMed
  3. BMC Cell Biol. 2007 Mar 06;8:10 - PubMed
  4. Science. 2000 Sep 15;289(5486):1938-42 - PubMed
  5. Mol Cancer Ther. 2005 Dec;4(12):1900-11 - PubMed
  6. J Clin Oncol. 2010 Feb 10;28(5):780-7 - PubMed
  7. PLoS Genet. 2008 Jul 04;4(7):e1000111 - PubMed
  8. J Clin Invest. 2003 May;111(9):1287-95 - PubMed
  9. Science. 2002 Dec 6;298(5600):1912-34 - PubMed
  10. Nat Rev Cancer. 2008 Aug;8(8):579-91 - PubMed
  11. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3775-80 - PubMed
  12. Clin Cancer Res. 2007 Jun 15;13(12):3713-23 - PubMed
  13. Nature. 2004 Mar 25;428(6981):431-7 - PubMed
  14. Nat Med. 2001 Feb;7(2):192-8 - PubMed
  15. Cell. 1987 Oct 9;51(1):33-40 - PubMed
  16. EMBO J. 1996 Jan 15;15(2):290-98 - PubMed
  17. Nat Med. 2001 Feb;7(2):186-91 - PubMed
  18. Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 - PubMed
  19. Oncologist. 2007 Apr;12(4):426-37 - PubMed
  20. Carcinogenesis. 2006 Sep;27(9):1729-38 - PubMed
  21. Blood. 2009 Jul 30;114(5):1110-22 - PubMed
  22. Cell. 2009 Aug 21;138(4):645-659 - PubMed
  23. Nat Rev Mol Cell Biol. 2006 May;7(5):359-71 - PubMed
  24. EMBO J. 2005 Aug 17;24(16):2885-95 - PubMed
  25. Nat Med. 2009 Sep;15(9):1023-30 - PubMed
  26. Curr Cancer Drug Targets. 2010 Aug;10(5):546-53 - PubMed
  27. Nat Chem Biol. 2006 Jul;2(7):358-64 - PubMed
  28. J Biol. 2003;2(4):27 - PubMed
  29. Cell. 1996 Dec 27;87(7):1171-80 - PubMed
  30. Cell Cycle. 2006 Aug;5(16):1779-87 - PubMed
  31. Oncologist. 2009 Apr;14(4):399-411 - PubMed
  32. Genes Dev. 2005 Feb 1;19(3):397-410 - PubMed
  33. Nat Rev Cancer. 2010 Feb;10(2):130-7 - PubMed
  34. Curr Opin Investig Drugs. 2009 Jun;10(6):597-605 - PubMed
  35. Oncogene. 2009 Dec 17;28(50):4409-20 - PubMed
  36. Cell Tissue Res. 2003 Oct;314(1):61-8 - PubMed
  37. Invest Ophthalmol Vis Sci. 2008 May;49(5):1836-42 - PubMed
  38. Nat Rev Genet. 2004 Jan;5(1):11-22 - PubMed
  39. Mol Cell. 2003 Sep;12(3):627-37 - PubMed
  40. Int J Cancer. 2006 Oct 15;119(8):1755-60 - PubMed
  41. Oncol Res. 2004;14(4-5):175-225 - PubMed
  42. J Pediatr Surg. 2007 Feb;42(2):386-9 - PubMed
  43. Cancer Res. 1999 Jan 1;59(1):99-106 - PubMed
  44. Genes Dev. 1994 Aug 15;8(16):1897-909 - PubMed
  45. Nat Med. 2007 Dec;13(12):1458-66 - PubMed
  46. J Natl Cancer Inst. 2005 Jan 5;97(1):14-21 - PubMed
  47. Cell. 1984 Jul;37(3):1035-42 - PubMed
  48. Mol Cancer Ther. 2007 Jul;6(7):2012-21 - PubMed
  49. J Clin Oncol. 2010 Jan 10;28(2):207-14 - PubMed
  50. Semin Cancer Biol. 2009 Oct;19(5):329-37 - PubMed
  51. Nat Med. 2001 Feb;7(2):199-205 - PubMed
  52. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5112-7 - PubMed
  53. Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):207-9 - PubMed
  54. Cell. 2010 Feb 19;140(4):460-76 - PubMed
  55. Nature. 2005 Jul 7;436(7047):78-86 - PubMed
  56. Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S81-5 - PubMed
  57. Cancer Res. 1996 Jan 1;56(1):100-4 - PubMed
  58. Blood. 2006 Aug 15;108(4):1243-50 - PubMed
  59. PLoS One. 2007 Nov 14;2(11):e1161 - PubMed
  60. Mol Biol Cell. 2007 Apr;18(4):1421-9 - PubMed
  61. Nat Rev Cancer. 2010 Mar;10(3):165-80 - PubMed
  62. Nature. 2005 Aug 11;436(7052):871-5 - PubMed
  63. Nat Rev Clin Oncol. 2009 Jul;6(7):395-404 - PubMed
  64. Blood. 2006 May 1;107(9):3531-6 - PubMed
  65. Nat Rev Clin Oncol. 2009 Oct;6(10):569-79 - PubMed
  66. J Biol Chem. 2003 Oct 17;278(42):40973-9 - PubMed
  67. J Exp Med. 2001 Sep 17;194(6):797-808 - PubMed
  68. Development. 2008 Nov;135(22):3755-64 - PubMed
  69. Nature. 2008 Jul 31;454(7204):656-60 - PubMed
  70. Nat Cell Biol. 2007 Dec;9(12):1401-12 - PubMed
  71. J Cell Biol. 2010 Jan 11;188(1):115-30 - PubMed
  72. N Engl J Med. 2003 Jul 31;349(5):427-34 - PubMed
  73. Cancer Cell. 2008 Apr;13(4):331-42 - PubMed
  74. Nat Clin Pract Oncol. 2007 Mar;4(3):181-9 - PubMed
  75. Nature. 2010 Apr 15;464(7291):1067-70 - PubMed
  76. N Engl J Med. 2007 Jul 5;357(1):39-51 - PubMed
  77. EMBO J. 2010 Apr 21;29(8):1377-88 - PubMed
  78. Trends Cardiovasc Med. 2007 Jul;17(5):145-51 - PubMed
  79. Mol Cancer Ther. 2009 Jan;8(1):55-63 - PubMed
  80. Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14819-24 - PubMed
  81. Methods. 2006 Nov;40(3):262-71 - PubMed
  82. Nat Rev Genet. 2006 May;7(5):373-84 - PubMed
  83. Clin Cancer Res. 2003 Jan;9(1):327-37 - PubMed
  84. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5118-23 - PubMed
  85. Clin Cancer Res. 1995 Nov;1(11):1311-8 - PubMed
  86. Cell. 2006 Oct 6;127(1):185-97 - PubMed
  87. Science. 2003 Mar 28;299(5615):2039-45 - PubMed
  88. Nat Rev Cancer. 2002 Aug;2(8):573-83 - PubMed
  89. Nature. 1995 Jul 6;376(6535):62-6 - PubMed
  90. Pathophysiology. 2010 Sep;17(4):229-51 - PubMed
  91. Mol Biol Cell. 2006 Feb;17(2):576-84 - PubMed
  92. Nat Rev Immunol. 2004 Jan;4(1):35-45 - PubMed
  93. Nat Cell Biol. 2008 Sep;10(9):1027-38 - PubMed
  94. Nat Med. 1996 May;2(5):561-6 - PubMed
  95. Clin Breast Cancer. 2009 Nov;9(4):258-61 - PubMed
  96. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16069-74 - PubMed
  97. EMBO J. 2001 Feb 15;20(4):672-82 - PubMed
  98. Mol Cell Biol. 2008 Aug;28(15):4843-50 - PubMed
  99. Dev Cell. 2002 Sep;3(3):411-23 - PubMed
  100. Cancer Res. 1997 Oct 15;57(20):4593-9 - PubMed
  101. Clin Cancer Res. 2006 Nov 1;12(21):6573-84 - PubMed
  102. J Pharmacol Sci. 2005 Jun;98(2):130-41 - PubMed
  103. Chem Biol. 2005 Mar;12(3):385-95 - PubMed
  104. Genes Dev. 2008 Dec 1;22(23):3268-81 - PubMed
  105. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3153-8 - PubMed
  106. J Clin Oncol. 2006 Jan 1;24(1):16-24 - PubMed
  107. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53 - PubMed
  108. Am J Pathol. 2009 Nov;175(5):2159-70 - PubMed
  109. Nat Rev Cancer. 2004 Jun;4(6):470-80 - PubMed
  110. BioDrugs. 2009;23(5):289-304 - PubMed
  111. J Cell Sci. 2004 Jun 1;117(Pt 13):2745-56 - PubMed
  112. Nature. 2006 Nov 9;444(7116):230-4 - PubMed
  113. J Exp Med. 2007 Oct 1;204(10):2349-62 - PubMed
  114. Clin Ther. 1999 Feb;21(2):309-18 - PubMed
  115. Pathophysiology. 2010 Sep;17(4):253-61 - PubMed
  116. Angiogenesis. 2007;10(3):167-82 - PubMed
  117. Cancer Cell. 2004 Oct;6(4):333-45 - PubMed
  118. Cancer Res. 2008 Jun 15;68(12):4754-62 - PubMed
  119. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579-86 - PubMed
  120. EMBO J. 2001 Sep 3;20(17):4762-73 - PubMed
  121. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15593-8 - PubMed
  122. J Clin Oncol. 2005 Feb 10;23(5):965-72 - PubMed
  123. Nat Rev Genet. 2008 Jul;9(7):554-66 - PubMed
  124. EMBO J. 1995 Dec 1;14(23):5884-91 - PubMed
  125. Science. 1992 Feb 21;255(5047):989-91 - PubMed
  126. Curr Cancer Drug Targets. 2008 Sep;8(6):446 - PubMed
  127. Oncogene. 2000 Nov 20;19(49):5548-57 - PubMed
  128. Mol Cancer Res. 2002 Nov;1(1):2-11 - PubMed
  129. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4299-304 - PubMed
  130. Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78 - PubMed
  131. J Clin Oncol. 2006 Jan 1;24(1):25-35 - PubMed
  132. J Biol Chem. 2001 Jul 6;276(27):25520-31 - PubMed
  133. Comb Chem High Throughput Screen. 2003 Jun;6(4):279-86 - PubMed
  134. Cancer Metastasis Rev. 2006 Jun;25(2):221-32 - PubMed
  135. FASEB J. 2006 Jul;20(9):1462-72 - PubMed
  136. Nat Rev Clin Oncol. 2009 Oct;6(10):587-95 - PubMed

Publication Types